Teva Pharmaceutical Industries Ltd. ADR 0.52% $23.98B ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

GSK (GSK) announced that the European Medicines Agency, EMA, has granted Priority Medicines, PRIME, Designation for GSK5764227, its B7-H3-targeted antibody-drug conjugate, ADC, being evaluated for ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at p1,388.50. Pick the best stocks and maximize ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

GSK is now looking to start a phase 3 trial in the first-line setting shortly, Abdullah said. The DREAMM-10 study will once again pit Blenrep against Darzalex, this time as part of front-line ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.